Mostrando entradas con la etiqueta Mercados. Mostrar todas las entradas
Mostrando entradas con la etiqueta Mercados. Mostrar todas las entradas

jueves, 5 de septiembre de 2024

BAYER: "Octopus move" / Lessons for management restructure. Brian D Smith


In these confidential meetings, I help them think about how their market is changing and how they can align their firm’s adaptation to those changes. Based on my academic research, I often use Darwinian evolution as a guiding framework for these meetings. This helps the execs make sense of their situation’s complexity and also offers a wealth of thought-provoking metaphors. This was especially true at one recent thoughtshop, which I will share with you.

Bill Anderson’s mutation

The thoughtshop happened just a few days after Bayer’s CEO Bill Anderson had announced a more than usually radical restructure, which involved not only some significant new appointments but also a pretty drastic delayering. It’s not always easy to see through the corporate PR-speak, but it seems clear that he is trying to accelerate the venerable company’s adaptation to our market’s changing social and technological environment. Frustrated by Bayer’s bureaucracy, Anderson is shrinking the leadership team and central management functions while pushing decision-making down the organisation. In the thoughtshop, this move became a point of discussion. Would it work? What would Charles Darwin predict for Anderson’s chances of success?

Nine brains


A good biological metaphor for what Bayer is trying to do is the octopus. In contrast to most other creatures, the octopus has a kind of distributed intelligence. Its central brain, wrapped around its oesophagus, contains only one third of its neurons and is helped by eight other brains, one in each limb, that together contain the remaining neurons. The nine brains seem to combine in a top-down/bottom-up coordination, with the limb-brains focused on making sense of their immediate environment and the central brain passing signals between them. This seems to work. Octopuses are phenomenally intelligent and have survived for millions of years. If Bayer can imitate them, then Anderson will deserve high praise.

Idea vehicles

Metaphors are more than writers’ devices. In science, they are a vehicle for carrying useful ideas from one subject area to another: Think of CRISPR’s molecular scissors and cell factories. They can be stretched too far but, used intelligently, metaphors are very useful. Applied to the question of whether Bayer’s restructure will work, they provide an answer that depends on two contingencies. 

_First, octopuses’ distributed brains work because their limb brains have evolved to be extraordinarily good at making sense of their local environment. Each of them processes the information from up to 280 suckers, each of which has 10,000 neurons that feel and taste. _Second, octopuses’ success is also due to coordination between limbs, which work together to push food into their mouths. Subsidiary sensing and central coordination are the two things that make octopuses so intelligent and effective. Without either, these creatures wouldn’t be the doyens of intelligence researchers that they are.

The Leverkusen displacement

As Donald Schön wrote, organisations learn by displacing ideas from one context to their own and, if he’s as smart as I think he is, Anderson will displace cephalopodologists’ ideas into Bayer’s Leverkusen office. He’ll ensure that his distributed decision-makers have the capabilities and resources to make sense of, and react to, their market sub-environment. At the same time, he’ll direct the much-reduced headquarters staff to be conduits and coordinators rather than controllers. Both of these tasks are much easier to write than to do and the success of Bayer’s reorganisation depends on its implementation. Anderson’s octopus move certainly could work, but whether it will or not hinges on another factor, clues to which lie in his public announcement.

Cultural artefacts

Anderson was quoted in the industry media as saying Bayer’s bureaucracy was the problem, not its culture. That suggests a gap in his understanding. Bureaucracy is an artefact of organisational culture, not separate from it. When he complains about small decisions needing multiple signatures, he’s observing a surface indication of a deep-seated culture that, like all organisational cultures, is persistent and pervasive. He can fix all the bureaucratic issues he wants, but if he doesn’t address the implicit values and ‘taken for granted’ assumptions that underlie them, they will come back to hinder even the most distributed intelligence. I’m very fond of Bayer and I really want its octopus move to be successful. That is more likely if Anderson is less complacent about the grand old firm’s culture.

Más

miércoles, 17 de julio de 2024

The renaissance of Alzheimer´s drug development


 

With 14 million people in Europe expected to suffer from Alzheimer’s and other forms of dementia by 2030, the race is on to find a treatment to not only slow its course, but even prevent the development of the disease.

Historically, market authorisations for neurological diseases have had significantly lower rates of success compared with other indications.

Between 2000 to 2015, the likelihood of approval for neurological drugs that entered phase 1 trials (8.4%) was below the mean across all indications (9.6%) and far below haematology (26.1%) and infectious diseases (19.1%). When considering neurodegenerative diseases and specifically Alzheimer’s disease (AD), the rate is even lower with only four drugs: donepezil; galantamine; memantine, and rivastigmine approved between 1996 and 2020.

These drugs, however, only treat the disease’s symptoms rather than the causes. This has largely been due to a lack of understanding of the mechanisms behind disease pathogenesis, with advances in AD happening at a significantly slower rate relative to other diseases. Despite being first discovered over 100 years ago, the complexity of the brain and limitations surrounding research/diagnostic methods and models have acted as barriers for AD drug development.

Recently, however, this trend has begun to shift. In 2021, while cancer drugs accounted for 30% of all new FDA approvals, neurology saw the second most approvals for the third time in a row (10%). 


The AD pipeline in particular saw major advancements with the (controversial) FDA accelerated approval of Biogen’s Aduhelm (aducanumab) in 2021, the first amyloid-targeting antibody for AD. The FDA approval of Eisai’s Leqembi (lecanemab) in July 2023 – with Lilly’s donanemab submitted but awaiting a currently delayed advisory committee meeting in 2024 (both of which also target amyloid) – continue to highlight the advancements happening in AD therapeutics.


A closer look at amyloid targeting treatments and beyond

Amyloid plaques, targeted by the aforementioned therapeutics, form from a protein known as amyloid-beta (Aβ), which is produced through the proteolytic cleavage of amyloid precursor protein (APP). The cleavage of APP has two different pathways known as the non-amyloidogenic and the amyloidogenic pathway. The non-amyloidogenic pathway results in soluble APP (sAPP) and a fragment known as P3 being released, with both being cleared from the brain. Alternatively, the amyloidogenic pathway, which is the main interest in AD, results in the generation of oligomeric Aβ40 or Aβ42, which are deposited within the brain and over time, through a process known as aggregation, form insoluble plaques.

.../... 

In the next 12 months, it is also likely there will be the approval of at least one more amyloid drug in Eli Lilly’s donanemab globally. In addition, potential approval of a subcutaneous formulation of Eisai’s Leqembi (currently requesting an FDA Fast Track designation) will offer patients greater accessibility due to not requiring access to a transfusion centre, with data showing increased efficacy and comparable safety to the current intravenous Leqembi.

Beyond 2024, the general consensus among HCPs and key opinion leaders active in the AD clinical space is that combination therapies with existing drugs for AD will start being developed, with therapeutic efficacy further enhanced by doing so. These could manifest in several ways including combining Aβ (Leqembi/donanemab) and TREM2-targeting drugs (AL002) or Aβ and tau (E2814)-targeting combination therapies.

Increased funding and greater public awareness of AD impact on people’s lives will continue to influence future innovation in these areas. The potential financial benefits are also certainly an incentive for drug developers with the Alzheimer’s market estimated to be $4.2bn in 2022 and expected to grow to $15.6bn by 2030. The financial burden on payers and governments has led to the recognition by regulatory bodies of an unmet need and is also contributing to advancements in AD therapeutics. With AD and other dementias responsible for a cost of $2.8trn in 2019 and expected to cost $4.7trn by 2023 globally, the race is truly on.

How the pipeline continues to develop may be dependent on the success of Leqembi, but as the first amyloid drug to be covered for reimbursement, it has paved the way for subsequent developments. While the actual clinical and commercial success of Leqembi is still to be determined, the market remains open, highlighting the requirement for further development.

 

Más...

miércoles, 29 de mayo de 2024

ESPAÑA: ROCHE compite con NOVARTIS...


 

El Ministerio de Sanidad dará luz verde a una nueva arma terapéutica contra el cáncer. Los técnicos del departamento que dirige Mónica García se reunieron el pasado 24 de abril para discutir sobre la financiación de diversos fármacos. El acta de esa reunión de la Comisión de Precios de Medicamentos, a la que ha tenido acceso este medio, se saldó con la aprobación de cinco nuevos medicamentos, entre los que destaca Lunsumio, un antitumoral desarrollado por Roche para tumores líquidos que podrá ser administrado en ambulatorios en lugar de en hospitales.

El informe técnico de la Agencia Española del Medicamento, necesario para recibir la autorización, explica que el medicamento deberá reforzar los resultados obtenidos en los ensayos clínicos realizados hasta la fecha. Mientras tanto, la Agencia aconseja posicionar el tratamiento "como una nueva opción terapéutica, en particular frente a tisagenlecleucel".

Es aquí donde se encuentra la batalla que se comenzará entre dos compañías cuyas sedes centrales están separadas por el río Rin en la ciudad de Basilea. Las pruebas para llegar al mercado que ha realizado Roche han sido en comparativa con la terapia CAR-T de Novartis: Kimriah.

miércoles, 15 de mayo de 2024

Argentina: BAGÓ cumple 90 años...


 

El laboratorio nacional Bagó cumplió nueve décadas en el mercado. Y para celebrar este hito la empresa llevó a cabo un evento en el Marriott ayer jueves 11 de abril. Fue una reunión interna en la que los hermanos Bagó repasaron los cimientos y la proyección de la compañía.

Ayer jueves 11 de abril el hotel Marriott recibió al staff completo del nacional Bagó. En un mega evento, el laboratorio festejó su 90 aniversario y todos los equipos tuvieron la oportunidad de repasar la visión de la familia fundadora junto a su mirada conjunta del negocio en el largo plazo.

El que dio las palabras de bienvenida fue el gerente general Edgardo Vázquez, quien se dirigió a los empleados e incluso a muchos ex Bagó que fueron parte del encuentro. El ejecutivo, que está al mando de la compañía desde más de un lustro, se refirió al recorrido de la empresa durante todos estos 90 años, a sus valores y pilares, y a el desarrollo e impulso que caracterizan a esta corporación nacional.

A posteriori, Mariana Arias entrevistó a Juan Carlos Bagó, en un espacio donde destacó al respeto, el trabajo en equipo, y la innovación como las columnas vertebrales de la compañía. Después, su hermano Sebastián Bagó brindó su visión más amplificada, la que repasó el avance de la salud a nivel mundial, así como el recorrido y ligazón de la Argentina y Bagó, entrelazando las décadas vividas.

Se resaltaron los valores, la resiliencia de la compañía ante los avatares de la historia económica argentina, y la ética del empleo, el trabajo en equipo, la lealtad, el respeto, la apertura a ideas nuevas y disruptivas. La velada finalizó con un video homenaje, un brindis y la entrega de estatuillas a Juan Carlos Bagó y Sebastián.

Durante la noche se repasó la historia de la empresa desde su fundación en 1934, en un salón vestido con los tonos magenta que caracterizan al laboratorio. Iniciada la década del 60, la empresa amplió su área de cobertura concretando las primeras exportaciones a Latam. Actualmente tiene presencia en 20 mercados de América Latina, Europa y Asia, y comercializa sus productos en 50 países de todo el mundo.

Según se informó en el 2023, la empresa cuenta con cuatro unidades de negocio, que generan 60 millones de unidades producidas. Esto implicó un crecimiento de más del 5% versus el año anterior, de acuerdo con lo informado. A su vez, se dio a conocer que la empresa invirtió $1.500 millones (u$s 4 millones al 2023) en tecnología y digitalización en plantas industriales, en el marco de un proceso de transformación tecnológica.

jueves, 11 de enero de 2024

Fármacos en Africa...

La Federación Internacional de Asociaciones de Fabricantes Farmacéuticos (IFPMA, por sus siglas en inglés) señala que un 25% de la carga mundial de las enfermedades afecta a las personas que viven en África, sin embargo, sólo el 2% de la investigación médica centrada en nuevas infecciones se origina en el continente. Además, la Organización Mundial de la Salud (OMS) indica que el continente importa un 94% de sus medicamentos y produce menos del 1% de las vacunas a nivel global. 

Entre otras razones, estas cifras se deben a que reciben una escasa, o ninguna, cobertura. A pesar de contar con una amplia demanda, ya que en la actualidad la salud global no cuenta con la variedad necesaria para enfrentar los problemas de salud específicos del continente. Además, enfermedades como el sida, la tuberculosis y la malaria perjudican a los países más pobres, los cuales no reciben la inversión necesaria. 


Con un panorama tan negativo, la IFPMA y la Fundación H3D colaboran desde 2021 con científicos de África que se encuentran en la mitad de su carrera para desarrollar sus habilidades y, así, ayudar a poner solución a un problema tan complejo. Recientemente, ambas partes han anunciado una nueva fase de tres años de colaboración, continuando con el objetivo de impulsar las habilidades y la capacidad necesaria para impulsar una mayor investigación y el desarrollo de nuevos medicamentos en África.

En concreto, durante este periodo se abordarán cuestiones como el fortalecimiento de los sistemas de salud, la expansión de la cadena de valor del ecosistema de innovación y la eliminación de las barreras que enfrentan los científicos africanos para abrir nuevos caminos en el descubrimiento de fármacos. 

Uno de los protagonistas, Richard Amewu, investigador principal del Grupo de Innovación de Medicamentos de la Universidad de Ghana, ha explicado que esta asociación entre la IFPMA y la Fundación H3D ha “dado credibilidad al continente”, lo que supone un gran paso para recibir más inversiones internacionales en investigación y desarrollo de fármacos. 

 Esta prórroga de la asociación se ha anunciado en la Conferencia sobre Salud Pública en África en Lusaka, donde el profesor Kelly Chibale, presidente y director ejecutivo de H3D-F y fundador y director de H3D resaltó que la colaboración entre ambas entidades les ha permitido crear y alimentar más programas, que acaban desencadenando “una visión aún más amplia”, entre los que se incluye el Acelerador de descubrimiento de fármacos Grand Challenges África.

Este se trata de un programa que busca promover la innovación científicaliderada por África para ayudar a los países a lograr mejor los Objetivos de Desarrollo Sostenible. Englobado en Grand Challenges, tratan de resolver los desafíos de ciencia, tecnología e innovación y salud de África, en búsqueda de generar un mayor impacto y servir a quienes más lo necesitan. 

 Por parte del subdirector general de IFPMA, Greg Perry, resaltó la importancia de “atraer, desarrollar y fomentar” el talento científico y la innovación a nivel local, que ayudará a garantizar que el continente africano sea parte de la cadena de valor del ecosistema de innovación y de innovación saludable. 

Estamos seguros de que nuestra asociación continua con la Fundación H3D es una inversión sostenible en el ecosistema de salud de África y esperamos con ansias lo que lograremos juntos en los próximos tres años”, añadió Perry.

miércoles, 5 de julio de 2023

Mergers and...Los m,ercados "se mueven"...selectivamente.

 


 

Merck – known as MSD outside the US and Canada – has said it will acquire Prometheus Biosciences for around $10.8bn, marking a significant boost to its immunology pipeline.

The deal will grant Merck access to the California-based biotech’s lead candidate, PRA023, being developed for ulcerative colitis, Crohn’s disease and other autoimmune conditions.

Prometheus announced positive results from a phase 2 study of the candidate in ulcerative colitis late last year, with 26.5% of patients in the PRA023 cohort achieving clinical remission, compared to 1.5% on placebo.

The company also reported positive results from a single-arm study evaluating the antibody in Crohn’s disease at the same time.

Commenting on the deal, Robert Davis, chairman and chief executive officer of Merck, said: “The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need.”

This transaction adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade,” he added.

Under the terms of the agreement, Merck will pay $200 per share. The transaction is expected to close in the third quarter of 2023.

 

GSK has said it will acquire Bellus Health for approximately $2bn in a deal that is set to expand the British drugmaker’s specialty medicines and respiratory pipeline.

The acquisition will grant GSK access to the Canadian biotech’s experimental drug, camlipixant, currently in phase 3 development for refractory chronic cough (RCC).

Current clinical data shows that by selectively inhibiting P2X3 receptors, camlipixant may reduce cough frequency with a relatively low incidence of dysgeusia – the taste disturbance associated with other medicines that broadly target the P2X2/3 receptor.

Bellus initiated a pair of phase 3 trials evaluating camlipixant in recent months, with data from the studies expected in the second half of 2024 and 2025.

Under the terms of the agreement, GSK will pay $14.75 per share in cash. The transaction is expected to close in the third quarter of this year.

Camlipixant is up against a rival RCC candidate, gefapixant, from Merck – known as MSD outside the US and Canada. The drug, which is also a P2X3 receptor antagonist, was denied US approval at the beginning of 2022, with the US Food and Drug Administration requesting additional efficacy information. Merck is expected to submit the information later this year.

Eli Lilly will sell its severe hypoglycaemia treatment, Baqsimi, to Amphastar Pharmaceuticals in a deal worth over $1bn, the two companies announced.

Under the terms of the definitive agreement, Amphastar will pay Lilly $500m at closing and an additional $125m after one year, with Lilly also eligible to receive sales-based milestone payments of up to $450m.

Baqsimi is the first and only nasally administered glucagon that can be used to treat severe hypoglycaemia – very low blood sugar – in diabetes patients aged four years and older.

Classed as a diabetic emergency, severe hypoglycaemia is a complication that can occur in diabetes patients who take insulin and certain anti-diabetic tablets.

The condition is characterised by altered mental or physical functioning, including confusion and disorientation, convulsions, loss of consciousness and coma.

Lilly launched Baqsimi in 2019 and it is currently available in 27 international markets, with worldwide sales totalling over $139m in 2022.

Amphastar, which is focused on developing, manufacturing and marketing injectable, intranasal and inhalation products, said it expects to provide ‘dedicated commercial investment’ to expand access to the treatment.

The transaction has been approved by the boards of directors of both companies and is expected to close in the second or third quarter of 2023.

Pharmaceutical Market Europe May 2023

jueves, 22 de junio de 2023

M&A: NOVARTIS buys CHINOOK


 

Swiss pharma giant Novartis announced that it will acquire kidney disease drug developer Chinook Therapeutics . The target rallied on the news, as a major takeover premium is being paid, but the deal could also make sense for Novartis, as this boosts its pipeline, which should improve the long-term growth outlook.


Novartis
, one of the largest pharma companies in the world, announced that it will acquire Chinook Therapeutics in a deal that values the target at $3.5 billion. At the time of writing, Chinook Therapeutics is up 58%, which can be attributed to the fact that Novartis offered a hefty takeover premium of more than 60%. Chinook is still trading slightly below the $40 takeover price, despite the jump its shares have experienced on the takeover news.

On top of the $40 per share, Novartis could pay up to $4 per share over the coming years, depending on whether Chinook will achieve a range of goals. This includes development milestones for Chinook's most important asset atrasentan.

While the deal is huge news for shareholders of Chinook Therapeutics, the $3.5 billion deal price is not overly large for Novartis - the company generated more than $13 billion of free cash flow over the last four quarters, meaning the takeover can be paid for with around three months' worth of NVS' free cash generation. Not surprisingly, Novartis does not need to issue any equity to finance this deal, thus there's no dilution investors have to worry about. In fact, Novartis ended the last quarter with around $15 billion in cash and equivalents, thus the company could pay for several deals of this size in a short period of time.

The Chinook Takeover Boosts Novartis' Pipeline

Novartis is one of the largest pharma companies in the world, thus it naturally is active in different therapeutic areas. It also owns a deep pipeline with a wide range of drug candidates. Some of these are new developments, in other cases, Novartis seeks to get drugs approved for additional indications while already selling the same drug in other indications.

Novartis' pipeline includes candidates in areas such as solid tumors, hematology, immunology, neuroscience, and many more. In total, the company has 48 phase III studies in place right now, as can be seen on its website here. A pharma company with a large and established business such as Novartis needs a deep pipeline, of course, as existing drugs that have been on the market for years go off patent from time to time. 

While sales for off-patent drugs do not drop to zero immediately, they generally decline over time, thus these revenues have to be replaced via a combination of the following factors:

- Increasing the price of its products, thereby generating higher revenue per patient.

- Increasing the number of patients on the company's medication for existing products, e.g. by increased marketing spending or by entering new geographic markets.

- Adding new product lines, either via the introduction of new drugs or by receiving approvals for existing drugs in additional indications.

The last point is highly important, and M&A helps. While Novartis would sport a sizeable pipeline even without any takeovers, M&A can add to a company's growth potential. Importantly, pharma companies also can use M&A in order to boost their presence in markets that are deemed attractive (by the company's management), but where the company's in-house expertise is lacking or where its own development efforts have not resulted in attractive products.


Chinook Therapeutics
is focused on kidney diseases, which is not a huge therapeutic area for Novartis yet. In recent years, Novartis generated the vast majority of its revenue and profit in other areas. The company's most recent quarterly report includes the following statement (emphasis by author):

We have a clear focus on five core therapeutic areas

_cardiovascular,

 _immunology, 

_neuroscience, 

_solid tumors and 

_hematology), 

with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential.

Novartis thus has not had a big presence in Chinook Therapeutics' focus area so far, but it looks like management deems this an attractive market to expand into. Precedence Research reports that the global nephrology (kidney disease) market size was $16 billion last year, and it forecasts that this market will grow at a mid-single-digit rate through the early 2030s. This is thus a sizable market with considerable growth over the next decade, although it should be noted that sales forecasts may turn out too high or too low eventually. Still, it seems highly likely to me that the global nephrology market will expand considerably in the long run - aging populations in many industrial countries will result in rising overall healthcare spending, and at the same time, more and more people in high-growth markets such as China and India can afford effective treatments for themselves.

Chinook Therapeutics does not have any drugs on the market so far, but that holds true for many smaller pharma companies. A major pharma company taking over a development-stage pharma company is relatively common, and it makes sense for both parties: The acquirer gets an attractive pipeline asset without spending gigantic sums of money - just a couple of months' worth of cash flow in this case. At the same time, the acquired company benefits from increased funding and the acquirer's expertise when it comes to the regulatory process, and, eventually, commercialization of the drug once approved. A global giant such as Novartis can leverage the sales potential of a drug (once approved) a lot faster and more efficiently compared to a small pharma company that has not established itself globally yet. Such deals thus oftentimes make sense for both involved parties, although there is, of course, still some risk for the acquirer - it's possible that the acquired company's pipeline assets turn out to not perform as well as expected, and in a worst-case scenario, no drug will be approved. The good news is that this would still be easily stomached for a company such as Novartis - the worst-case scenario of spending $3.5 billion without getting any new drug out of this deal is not a company-threatening event at all.


Chinook Therapeutics
' lead agent, atrasentan, is being evaluated for the treatment of IgA Nephropathy. There are competing drugs on the market, such as Calliditas Therapeutics' Tarpeyo, which was the first IgAN treatment to receive approval in the US. But since Tarpeyo was approved not too long ago, it's not too late to enter this market with a new drug. It's expected that this market will expand significantly in the coming years, and it seems likely that more than one company can make money selling an IgAN treatment. With NVS' global presence and established wide sales network, commercializing atrasentan would not be too hard - if the drug candidate performs well and receives approvals.

Más


miércoles, 14 de junio de 2023

EU’s Pharmaceutical Strategy for Europe / CE revisa Normas

 


As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by

 _reducing regulatory exclusivity, 

_speeding up review processes and reinforcing supply chains will also, according to the EC, support innovation and 

_boost the EU pharma industry’s competitiveness. 

 Innovators claim the proposed changes will do just the opposite.

After a number of postponements, the European Commission (EC) at last presented its proposal for the reform of the European bloc’s medicines legislation, its first major overhaul in 20 years. The EC claims that apart from promoting access, the reform will create an environment in Europe for “world-class innovation.” And while generics makers and patient groups applaud the reform, the innovative pharma industry sees it as a hit to the sector’s competitiveness, much like the Inflation Reduction Act in US or the recent tax hikes for UK drugmakers. One of the major issues the new legislation seeks to address is the existing access inequality across Europe with the bloc’s poorer countries normally getting new medicines years after their higher-income counterparts. As an example, Poland and Romania typically wait an average of two years longer to access a new medicines than patients in Germany.

To change this, the proposal puts forth a two-year reduction of the standard 10-year regulatory exclusivity period while introducing incentives for companies to obtain additional competition-free periods. Most importantly, drug makers will be able claim back two years by launching their medicines in all 27 EU markets within two years from the date the marketing authorization is granted. Other ways they can win back competition-free time would be by addressing an unmet medical need, or treating additional disease targets with the same drug.

In innovators’ view, access delays are not a product of favouritism towards richer countries but occur after companies have filed for pricing and reimbursement and are awaiting decisions and the proposed changes will only serve to undermine innovation. “The approach set out in the pharmaceutical legislation, penalizing innovation if a medicine is not available in all member states within two years is fundamentally flawed and represents an impossible target for companies,” said Nathalie Moll, Director General, EFPIA in a release.

For the EUCOPE, the organisation that represents small and mid-sized innovative European pharma companies, the proposal introduces more risk and unpredictability while reducing incentives for innovation and investment. “The Commission’s revision includes troubling proposals … which risk reducing the EU’s global competitiveness in life sciences, thereby limiting the development and availability of innovative therapies,” said EUCOPE Secretary-General Alexander Natz.

Ver

domingo, 30 de abril de 2023

La HEROÍNA de BAYER que se oculta...

 


Estamos en 1.898. Sólo 11 días después de lanzar al mercado la conocida Aspirina, los laboratorios Bayer empiezan a comercializar un nuevo y revolucionario producto: Heroína

El nombre Heroin, deriva del término heroisch, que en alemán significa heroico, pues así es como dijeron sentirse quienes probaron la sustancia durante los estudios previos a su comercialización: como héroes.

 Los anuncios a nivel mundial aseguran que, "al revés que la morfina”, la nueva sustancia produce un aumento de la actividad y hace desaparecer todo tipo de tos. 

A principios de 1900, algunas sociedades filantrópicas de EEUU llegan a distribuir muestras gratuitas de heroína vía correo para los adictos a la morfina que desean rehabilitarse. En España, Bayer aprovecha el invierno de 1912 para lanzar una intensa campaña de publicidad de su “jarabe de heroína”.


Después de haber sido aprobada por la American Medical Association, Bayer vende la heroína como eficaz e inocuo sustitutivo de la morfina, lo cual es absolutamente erróneo, pues se trata de una droga altamente adictiva. El proceso de transformación de la sustancia en el hígado da la clave del asunto: la heroína vuelve a convertirse en morfina dentro del cuerpo. 

En 1913 Bayer detuvo la producción de heroína y borró todo este embarazoso asunto de sus archivos. De hecho, si haces una búsqueda en su web (http://www.bayer.com/) utilizando la palabra clave “heroin” obtendrás exactamente cero resultados.

 

Tomado del Blog "Coscorrón de razón"